Skip to main content

Table 1 Clinical and genomic characteristics of the metaplastic PDX models

From: Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

IDType of graftAge at diagnosisBRCA mutational statusTNMBreast surgeryNode surgeryHistologic typeLymphovascular invasionSBR gradeChemotherapy (CT)Type of CTRTLocal relapseDistant relapseMFS (months)OS (months)
HBCx-66Residual disease post NCA38BRCA1200MastectomyLymphadenectomyFusiformNo3PrimarySequentialYes006969
HBCx-90Residual disease post NCA77No mutation4d00MastectomyNoFusiformYes2PrimaryTaxane-basedYes1111.511.5
HBCx-130Residual disease post NCA73No mutation200MastectomySentinel lymph node biopsySquamousNo3PrimarySequentialYes111922
HBCx-162Residual disease post NCA48No mutation200TumorectomySentinel lymph node biopsyChondroid and fusiformNo3PrimarySequentialYes001414
HBCx-165Primary breast cancer89No mutation200TumorectomySentinel lymph node biopsySquamousNo3AdjuvantCapecitabineYes011214
HBCx-178Residual disease post NCA61No mutation200TumorectomySentinel lymph node biopsySquamousNo3PrimarySequentialYes0099
HBCx-23Primary breast cancer41No mutation100TumorectomyLymphadenectomyChondroid and fusiformYes3AdjuvantAnthracyclin-basedYes008383
HBCx-60Primary breast cancer30No mutation310MastectomyLymphadenectomyFusiformNo3AdjuvantSequentialYes01103106
HBCx-70Residual disease post NCA51No mutation200MastectomyLymphadenectomySquamous and chondroidNo3PrimarySequentialYes011527
  1. TNM tumor, node, metastasis classification, SBR Scarff Bloom and Richardson, CT chemotherapy, RT radiotherapy, MFS metastasis-free survival, OS overall survival